Urotensin II, a peptide hormone from the caudal neurosecretory system of the teleost, Gillichthys mirabilis, was isolated by using classical chromatographic techniques and high-performance liquid chromatography (HPLC). Direct microtechniques for sequence determination were used to establish its structure. Urotensin II from Gillichthys is a 1363-dalton dodecapeptide with the amino acid sequence AlaGly-Thr-Ala-Asp-Cys-Phe-Trp-Lys-Tyr-Cys-Val. This sequence is homologous with somatostatin in positions 1 and 2 and 7-9. The sequence has been verified by the production of a bioactive synthetic urotensin II. The possible chemical and physiological significance of its homology to somatostatin is discussed.
.
MATERIALS AND METHODS
Source of Urophyses. Culhichthys mirabilis, 10-15 cm long, were obtained from San Francisco Bay. The urophyses dissected from freshly killed animals were dried in acetone before storage in a desiccator at -4°C until used.
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Isolation of UII. UII purification was carried out as described (8) with the following modifications. Gel-filtration chromatography on a 1 X 28 cm column packed with Bio-Gel P-6 (Bio-Rad), which was swollen in 0.2 M ammonium acetate buffer (pH 5.5), was performed at a flow rate of 100 Al/min.
The column was pretreated with 1.0 ml of 10% (wt/vol) bovine serum albumin to minimize adsorptive losses of UII. Bioassay. Biological activity of the hormone was determined by the trout hindgut contraction assay as described by Zelnik and Lederis (9) and Chan et al. (10) .
Amino Acid Analysis. Peptide samples (2) (3) (4) (5) (6) (7) (8) (9) (10) ,Ag) were hydrolyzed in vacuo for 24 or 48 hr in 3 M p-toluenesulfonic acid containing 0.2% 3-(2-aminoethyl)-indole (11) . Amino acids were separated on a Beckman 121MB analyzer with a twocolumn system (12) . Cysteine in the peptide was converted to either the S-methyl derivative by reaction with trimethyl phosphate after reduction with 2-mercaptoethanol (13) or to cysteic acid by performic acid oxidation (14) . Tryptophan was quantitatively recovered either unreacted or as the S-methylated peptide but was destroyed by performic acid oxidation. The S-methylated peptide (10 nmol) was digested with carboxypeptidase A for 40 min and 3 hr, and the released amino acids were quantified on the amino acid analyzer.
NHrTerminal Sequencing. The S-methylated or performic acid-oxidized peptide (2-6 nmol) was subjected to automatic Edman degradations on a modified Beckman 890C sequenator. The modifications are similar to those described by WittmanLiebold (15) , including an improved reagent/solvent delivery system, improved vacuum system, reagent/solvent purification, and automatic conversion of anilinothiozolinone to phenythiohydantoin (>PhNCS) derivatives of amino acids (16 Subsequent analysis of the performic acid-oxidized peptide gave high yields of cysteic acid (but no tryptophan) and reduced yields of tyrosine. This analysis showed two residues of cysteine per molecule.
NH2-terminal sequence analysis of S-methylated UII (2 nmol) (Fig. 3) gave an unambiguous sequence through cycle 10, but left some doubt as to the order of the last two residues, cysteine and valine. Subsequent sequence analysis of 4-6 nmol of S-methylated or performic acid-oxidized UII failed to resolve this problem. Digestion of S-methylated UTI with carboxypeptidase A resulted in a rapid release of valine followed by a slower release of S-methyl cysteine and tyrosine (lysine was not released with this enzyme). These data strongly suggested that valine was COOH-terminal and cysteine was the penultimate residue.
To confirm the sequence of UTI, two peptides were synthesized on a solid-phase Beckman peptide synthesizer. One peptide was identical to the proposed sequence in Fig. 3 ; the other was identical through position 10 but ended in Val-Cys. The former synthetic peptide had substantial biological activity and coeluted with authentic UTI on reverse-phase HPLC, but the latter peptide had no activity and eluted on HPLC analysis with a retention time of 16.2 min, as opposed to 13.0 min for native UTI. These data further confirm the proposed amino acid sequence for UTI. Details of the synthesis, characterization, and biological-activity studies of the synthetic peptides will be presented elsewhere. DISCUSSION The present work reports two important advances in the study of caudal neurosecretion. First, the development of a rapid isolation method, which is applicable to the isolation of small amounts of hormone from fresh tissue, makes possible studies of UTI biosynthesis and axonal transport. Because of the clear chemical relationship between somatostatin and UTI, information on the biogenesis of urotensin II derived from studies of the isolated caudal neurosecretory system in vitro may also be relevant to study of the biogenesis of somatostatin.
Second, the structural definition of UII has made it possible both to prepare synthetic hormone and to expand our concepts of possible UII functions as a result of its homology with somatostatin. The availability of synthetic UII will provide large Proc. Natl. Acad. Sci Yields were calculated by comparison with authentic standards after normalization of recoveries based on the inclusion of the internal standard >PhNCS-aminoisobutyric acid in the samples; >PhNCS-amino acids not shown were not present at significant levels above background. Cysteine was identified as either the S-methyl derivative (shown here) or as cysteic acid after performic acid oxidation (in this case tryptophan is destroyed); in either case, cysteine was not recovered in high enough yield to make an identification at cycle 11. quantities of material for extensive physiological studies and for the production of antibodies.
The NH2-terminal sequence analysis of UII demonstrates the sensitivity and utility of direct microsequencing with a modified spinning cup sequencer. Although Hunkapiller and Hood (17, 18) have reported successful sequence determinations of small peptides through the COOH terminus, it was difficult for us to obtain the last two residues of UII in high enough yield to permit an unambiguous assignment. We reasoned that performic acid-oxidized UII would be more strongly retained in the spinning cup by virtue of the ionic interaction of cysteic acid with the polycation carrier polybrene, but this was not the case. It may be that the contribution to peptide washout (organic solubility) of the aromatic residues at the COOH terminus of this peptide outweighed the ability of polybrene to retain even the performic acid-oxidized peptide in the spinning cup.
The amino acid composition and sequence analysis are in excellent agreement .and indicate a molecular size of 1363 daltons for UIL. The high yield of the NH2terminus argues that it possesses a single unblocked peptide chain. The homology between UII and somatostatin is striking (Fig. 4) . Holladay et al. (19, 20) have studied the structure-function relationships of somatostatin and have deduced that the Phe7-Trp8-Lys9 sequence is essential for biological activity. This sequence is also found in UTI. In somatostatin, the presentation of this active site is maintained by the hydrophobic base-stacking interaction of phenylalanines at positions 6 and 10 (21, 22) as indicated by the broken line in Fig. 4 . In urotensin II, this arrangement is assured by the disulfide bond between the cysteines at 6 and 10. Veber et al. (21) have synthesized a somatostatin analog with a cysteine disulfide ring in exactly this same arrangement, which resulted in increased potency over natural somatostatin in in- 1 5 hibiting the release of glucagon, insulin, and growth hormone. Thus, the structure of UII represents a surprising confirmation of what has already been demonstrated by synthetic improvements in the laboratory on a naturally occurring peptide hormone.
The preservation of the NH2-terminal Ala-Gly sequence in UII suggests a possible contribution of these two "tail" residues to receptor binding. Previous studies have demonstrated that replacement with proline of Thr at position 10 but not of Asn at position 5 results in loss of biological activity for somatostatin (21) . It is noteworthy that Asn5 and Thr'0 in somatostatin are replaced in UII with Asp5 and Tyr'0, respectively. These replacements suggest that these are equivalent replacements in terms of the structural interactions between these and other residues. In fact, it has been suggested that Asn5 interacts with Thr'2 and Thr'0 with the carbonyl of Phe7 in somatostatin (21) . In the light of these data, it is likely that Asn5 or Asp5 can hydrogen bond with Thr'2 or Val'2, and ThrI0 or Tyr'0 can hydrogen bond with Phe7 in the native peptides. The remaining amino acids appear to be nonessential by comparison of somatostatin with both synthetic analogs (23, 24) and with UII.
The fact that UII is a naturally occurring somatostatin analog raises interesting questions about the relative functions of these two hormones in fishes. An important similarity between these peptides involving control of Cl-flux is emerging: somatostatin inhibits HGO secretion by the stomach (25) and also inhibits Clexcretion stimulated by vasoactive intestinal peptide in the elasmobranch rectal gland (26); UII inhibits Cl-extrusion by the skin of the teleost, Gillichthys mirabilis (27) . UII substitutes for somatostatin as an inhibitor of in vitro prolactin release in the fish Tilapia (unpublished results). Furthermore, as indicated in our discussion of chemical similarities between the hormones, (29) describing the presence of two somatostatin-like peptides in catfish pancreas. The smaller of the two, pancreatic somatostatin I, is 22 amino acids in length and has considerable homology with somatostatin, including the positions of cysteines and the critical 7-9 positions. Pancreatic somatostatin I is homologous with urotensin II only in the 7-9 positions.
